Post-earnings recap
Reported
Tue, Aug 5, 2025
EPS actual
$-1.90
EPS est.
$-3.64
EPS surprise
+47.80%
1-day move
+8.59%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Madrigal Pharmaceuticals reported a narrower-than-expected loss in EPS, which led to a positive stock reaction, rising 8.59% in one day. The company did not provide revenue figures or future guidance, but management's comments suggest they are focused on their ongoing projects. Investors may view the EPS beat as a sign of operational improvement.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.90 | N/A | +47.80% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting operational progress. They emphasized their commitment to pipeline development.
We are pleased with our progress despite the challenges in the market.
Our focus remains on advancing our pipeline and achieving key milestones.